dont be upset about pnv. I suggest just put arx and pnv side by side and look at everything not just revenue versus market cap. Check out history, product differentiation, infection rates, pricing, cap raises, owner selling and buying, platform opportunities etc etc.
whatever you conclude is best then go hard on that one and dont even worry about the other one. If you are undecided then hedge your bets.
News: ARX Aroa Biosurgery Posts FY22 Product Sales Guidance Of $30M-33M, page-17
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.0¢ |
Change
-0.005(0.76%) |
Mkt cap ! $223.7M | |||
| Open | High | Low | Value | Volume |
| 65.5¢ | 66.0¢ | 64.0¢ | $248.4K | 382.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1587 | 63.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.5¢ | 24599 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| ARX (ASX) Chart |